share_log

信达生物(01801.HK):国家药监局受理玛仕度肽治疗2型糖尿病的新药上市申请

Innovent Bio (01801.HK): National Medical Products Administration accepted the new drug application for market approval of Marstondipeptide for the treatment of type 2 diabetes.

Gelonghui Finance ·  Aug 1 04:31

Innovent Bio (01801.HK) announced that the Centre for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has officially accepted the new drug application (NDA) for the dual agonist of glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR), mazdapptide (research and development code: IBI362), for the treatment of type 2 diabetic patients (T2D) to control blood sugar in adults.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment